| Literature DB >> 33981219 |
Bahare Salehi1, Cristina Quispe2, Muhammad Imran3, Iahtisham Ul-Haq4, Jelena Živković5, Ibrahim M Abu-Reidah6, Surjit Sen7,8, Yasaman Taheri9, Krishnendu Acharya7, Hamed Azadi10, María Del Mar Contreras11, Antonio Segura-Carretero12,13, Dima Mnayer14, Gautam Sethi15, Miquel Martorell16,17, Ahmad Faizal Abdull Razis18,19, Usman Sunusi19,20, Ramla Muhammad Kamal19,21, Hafiz Ansar Rasul Suleria22, Javad Sharifi-Rad9,23.
Abstract
Nigella is a small genus of the family Ranunculaceae, which includes some popular species due to their culinary and medicinal properties, especially in Eastern Europe, Middle East, Western, and Central Asia. Therefore, this review covers the traditional uses and phytochemical composition of Nigella and, in particular, Nigella sativa. The pharmacological studies reported in vitro, in vivo, and in humans have also been reviewed. One of the main strength of the use of Nigella is that the seeds are rich in the omega-6 fatty acid linoleic acid and provide an extra-source of dietary phytochemicals, including the bioactive thymoquinone, and characteristics saponins, alkaloids, and flavonoids. Among Nigella species, N. sativa L. is the most studied plant from the genus. Due to the phytochemical composition and pharmacological properties, the seed and seed oil from this plant can be considered as good candidates to formulate functional ingredients on the basis of folklore and scientific knowledge. Nonetheless, the main limations are that more studies, especially, clinical trials are required to standardize the results, e.g. to establish active molecules, dosage, chemical profile, long-term effects and impact of cooking/incorporation into foods.Entities:
Keywords: Nigella; cancer; functional ingredients; metabolic syndrome; pharmacological properties; thymoquinone
Year: 2021 PMID: 33981219 PMCID: PMC8107825 DOI: 10.3389/fphar.2021.625386
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Some traditional uses of Nigella species.
| Species | Traditional use | Country | References |
|---|---|---|---|
|
| |||
| | To treat lung, brain and skin | Palestine | ( |
| | To treat abdominal pain and to facilitate delivery | Palestine | ( |
| | To treat menstrual cycle problems | Iran | ( |
| | To treat cancer | Palestine | (( |
| | To treat diuretic, analgesic, insomnia, dizziness, tinnitus, amnesia, and bronchial disorders | China | ( |
| | To ease bowel and indigestion problems and to manage diabetes | India | ( |
| | To manage pain during menstruation and diabetes | Bangladesh | ( |
| | Curative effects in bacterial-caused diseases, sexual tonic, to manage lactation and to decrease mental disturbances | Pakistan | ( |
| | To treat malaria | Malaysia | ( |
|
| |||
| | Hypoglycemic and hypotensive agent | Algeria | ( |
| | Wooden steem: To treat jaundice. Seeds: Hypotensive agent and to treat heart diseases, headaches, nasal congestion, toothache, and against intestinal worms | Egypt | ( |
| | Hypoglycemic and hypotensive agent and to deal with digestive, respiratory, and cardiovascular problems, and allergy | Morocco | ( |
|
| |||
| | Galactagogue (seed) and against trachoma | Italy | ( |
| | Antihelmintic (for children) and to treat haematuria and skin diseases (itchiness and eczema) | Serbia | ( |
FIGURE 1Fatty acids in fixed oils from Nigella seeds.
FIGURE 2Phytochemical components in essential oils from Nigella seeds.
Main volatile compounds in essential oils from Nigella seeds.
| Compound name | Source (origin) | Relative amount (%) | References |
|---|---|---|---|
| Thymoquinone |
| 0.1, 3.7, 3.0, 33.1–38.4a, 77.2–86.2b, 0.6, ND, 3.8 | ( |
|
|
| ND, 33.8, 60.5, ND, ND, 14.8, 49.5, 33.8 | ( |
| Dithymoquinone |
| ND, ND, ND, ND, ND, ND | ( |
| Thymohydroquinone |
| ND, 0.4, 1.1–2.3a, ND, ND, ND | ( |
| Carvacrol |
| ND, 2.4, 0.8–2.0a, ND-7.9, 1.6, 0.6, ND | ( |
| Thymol |
| ND, ND, 5.3–17.0a, ND, ND, 26.8 | ( |
| α-Thujene |
| ND, 6.9, ND, ND-0.4b, 2.4, 18.9, 3.3 | ( |
| α-Pinene |
| ND, 1.7, ND, ND, 1.2, 1.2, 5.4, 0.7 | ( |
| β-Pinene |
| ND, 2.4, ND-0.4a, ND, 1.3, 4.3, 1.1 | ( |
| γ-Terpinene |
| ND, 3.5, 12.9–27.5a, ND-0.6b, 0.5, 2.5, 2.4 | ( |
|
|
| Tr, ND, ND, ND, 38.3 | ( |
| β-Elemene |
| 69.0, 73.2, 5.5 | ( |
ND, Not detected/reported; C, China; I, India; Ir, Iran; E, Egypt; M, Morocco; T, Tunisia; Tk, Turkey; Tr, traces.
Depending on the extraction method and conditions.
Depending on the origin.
FIGURE 3Example of chemical structures of alkaloids and saponins reported in N. sativa.
FIGURE 4Example of chemical structures of phenolic compouds reported in N. glandulifera, N. sativa, N. damascena, and N. arvensis.
Example of phenolic compounds found in Nigella species.
| Compound name | Source (origin) | Amount (mg/g) | References |
|---|---|---|---|
|
|
| NR, 0.002 | ( |
| Gallic acid |
| 0.3–1.0 | ( |
| Chlorogenic acid |
| 0.02–0.04 | ( |
| Syringic acid |
| 0.01–0.02 | ( |
| Vanillic acid |
| 2.2–3.5 | ( |
|
|
| 0.01–0.02 | ( |
| Ferulic acid |
| 0.04–0.13 | ( |
|
|
| 0.03–0.05 | ( |
| (–)-Epicatechin |
| 0.01–0.02 | ( |
| (+)-catechin |
| 0.1–0.3 | ( |
| Quercetin |
| NR, 0.002–0.005 | ( |
| Apigenin |
| 0.003–0.005 | ( |
| Amentoflavone |
| 0–0.001 | ( |
| Quercetin |
| 0.014, NR, NR | ( |
| Quercitrin |
| 0.020, 0.004 | ( |
| Hyperoside |
| 0.001 | ( |
| Kaempferol |
| 0.006, NR, NR, NR | ( |
| Kaempferol-3- |
| ND, tr, ND, ND, tr, 3.4–6.1 | ( |
A, Austria; C, China; CR, Czech Republic; E, Egypt; Et, Ethiopia; F, France; G, Germany; I, Italy; J, Jordan; NR, Not reported; R, Romania; S, Syria; T, Tunisia; Tk, Turkey; SA, Saudi Arabia.
It depends on the salinity tested.
FIGURE 5Example of phytosterols and stanols reported and other terpenes in Nigella.
FIGURE 6Chemical structure of salfredin B11, nigephenol A-C and of nigelladine A–C and nigellaquinomine.
Clinical trials on effect of Nigella sativa to various system disorders, diseases and conditions.
| Intervention | Application, duration | Type of study | Number of patients/study designa | Control | Main effectsa | References | |
| Powdered | Oral application for 8 weeks, 2 g of powder per day | Double-blind placebo controlled randomized clinical trial | 40 patients with HT (aged between 22 and 50 years) | Placebo (starch) | ↓ body weight and BMI, ↓ TSH and anti-TPO antibodies, ↑ T3, ↓ serum VEGF concentration | ( | |
|
| Oral application for eight weeks | Randomized double-blind trial | 40 patients with HT, 22–50 years | Placebo (starch) | ↓ serum IL-23, ↓ TSH and anti-TPO antibodies, ↑ serum T3, ↓ body weight | ( | |
|
| Oral application for 8 weeks, 2 g per day | Double-blind placebo controlled randomized clinical trial | 40 patients with HT (aged between 22 and 50 years) | Placebo (starch) | ↓ serum LDL and T3, ↑ HDL | ( | |
|
| Oral application of 500 mg in combination with 500 mg of metformin, 10 mg atorvastatine, 150 mg aspirin | Randomized clinical trial | 80 patients with metabolic syndrome and poor glycemic control (HbA1C>7%) | 500 mg of metformin, 10 mg atorvastatine, 150 mg aspirin | ↓ FBG, PPBG, HbA1c, LDL | ( | |
|
| Oral application for 3 months, 2.5 mL two times daily | Double-blind placebo controlled randomized clinical trial | 70 patients with type II diabetes | Mineral oil | ↓ FBG, PPBG, HbA1c | ( | |
|
| Oral application of 2g powder daily, for one year in addition to their standard medications | Double-blind placebo controlled randomized clinical trial | 114 patients with type 2 diabetes on standard oral hypoglycemic drugs | Placebo (charcoal) | ↓ FBG, HbA1c, TBARS ↑ TAC, SOD, GSH | ( | |
|
| Oral application of 3g oil daily, for 12 weeks | Double-blind placebo controlled randomized clinical trial | 72 patients with diabetes type 2 | Sunflower oil gel capsules | ↓ FBG, HbA1c, TG, LDL | ( | |
|
| Oral application of 2.5 mL two times daily for two months | Double-blind placebo controlled randomized clinical trial | 68 healthy men 20–45 years of age with infertility lasting more than one year | Liquid paraffin | Sperm count, motility, morphology and semen volume, pH and round cells were improved significantly | ( | |
|
| Two test groups received 100 and 200 mg of extract twice a day for 8 weeks | Double-blind placebo controlled randomized clinical trial | 119 healthy male volunteers, aged 35 to 50 | Placebo | ↓ systolic and diastolic BP in a dose-dependent manner | ( | |
|
| Oral application of 2.5 mL oil two times per day for 8 weeks | Randomized, double-blind placebo-controlled trial | 70 healthy volunteers aged 34–63 years | Mineral oil | ↓ systolic and diastolic BPs | ( | |
|
| 6 mg/kg daily, for 30 days | Prospective and double-blind clinical study | 66 patients with allergic rhinitis | Placebo | ↓ nasal mucosal congestion, nasal itching, sneezing attack, runny nose, turbinate hypertrophy, and mucosal pallor during the first 2 weeks of the study | ( | |
|
| 2 puffs/day of | Randomized double-blind placebo-controlled trial | 65 patients with mild to moderate chronic rhinosinusitis | Placebo (2 puffs/day of sodium chloride spray 0.65%) | Lund–McKay, lund Kennedy, and Sino-nasal outcome Test-22 scores significantly decreased in the intervention group | ( | |
|
| Topical application, twice a day for 6 months | Randomized, double-blind clinical trial | 52 patients with vitiligo lesions | Fish oil | Reduction in size of lesions | ( | |
|
| Ointment (1 G) topically applied on eczematous lesions twice a day for a period of 4 weeks | Randomized double-blind placebo-controlled trial | 60 patients with hand eczema, 18–60 years | Betamethasone and eucerin | ↓ Dermatology life quality index score in | ( | |
|
| 12 weeks, group I: 10% w/w ointment with | Randomized clinical trial | 60 patients with mild to moderate plaque and palmoplanter psoriasis | - | Group I—total healing of psoriatic lesions, with good response in 65% of patients, and a relapse rate of 31% four weeks after cessation of treatment; group II—good response in 50% of patients, with a relapse rate of 50% observed four weeks after application; group III—total cure of lesions, and good responses in 85% of patients, with a relapse rate of 18% | ( | |
|
| Two placebo capsules daily for 1 month, followed by a month of NS oil capsules 500 mg twice per day | Placebo controlled clinical trial | 40 female atients with rheumatoid artritis | Placebo (two starch capsules per day) | ↓ disease activity score, ↓ number of swollen joints and the duration of morning stiffness | ( | |
|
| 500 mg oil capsules two times daily for 8 weeks | Randomized, double-blind, placebo-controlled clinical trial | 42 patients with rheumatoid artritis | Placebo | ↑ IL-10, ↓ MDA, ↓ NO | ( | |
|
| Topical application twice a day (in the morning and night) for 21 days | Double-blind, parallel, clinical trial | 52 pateints with osteoarthritis, 60–80 years | Diclofenac gel | Better pain relief effect compared to diclofenac gel according to KOOS score (38.88 ± 17.84 and 50.33 ± 20.38, respectively) | ( | |
|
| Oral administration: 500 mg in capsules (twice a day for 9 weeks) | Randomized study | 20 healthy humans | Placebo: Psyllium seed husk in capsuels | Improvement in the parameters studied: Score of logical memory tests, attention test (letter cancenlation test and trail making test), cognitive test (Scroop)etc. | ( | |
aBMI, body mass index; BP, blood pressure; FBG, fasting blood glucose; HbA1c, hemoglobin A1c; HT, Hashimoto’s thyroiditis; IL, interleukin; LDL, low density lipoprotein; MDA, malondialdehyde; PPBG, postprandial blood glucose; T3, total triiodothyronine; TAC, total antioxidant capacity; TBARS, thiobarbituric acid reactive substances; TG, triglycerides; TPO, thyroid peroxidase; TSH, thyroid-stimulating hormone; VEGF, vascular endothelial growth factor.